BTK and autoimmune disease: Beyond JAK–STAT inhibition, several other pathway inhibitors, including phosphoinositide 3‐kinase inhibitors (PI3K),195 MAP kinase‐interacting serine/threonine‐protein kinase 1/2 (MNK1/2)inhibitors196 and Bruton's tyrosine kinase (BTK) inhibitors,197, 198 have been implicated in autoimmune diseases and reducing irAEs in solid tumours 189 (Figure 6).